[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://www.lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 72, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 82734, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 65, "title": "Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1021376, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 750442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 63, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary K. Lee Ph.D.", "age": 47, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark A. Meltz J.D.", "age": 50, "title": "General Counsel & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Tomlin", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.46, "open": 25.38, "dayLow": 24.86, "dayHigh": 25.74, "regularMarketPreviousClose": 25.46, "regularMarketOpen": 25.38, "regularMarketDayLow": 24.86, "regularMarketDayHigh": 25.74, "payoutRatio": 0.0, "beta": -0.11, "forwardPE": -30.059525, "volume": 33517, "regularMarketVolume": 33517, "averageVolume": 45755, "averageVolume10days": 60410, "averageDailyVolume10Day": 60410, "bid": 18.31, "ask": 29.15, "bidSize": 2, "askSize": 2, "marketCap": 535759968, "fiftyTwoWeekLow": 7.65, "fiftyTwoWeekHigh": 25.74, "allTimeHigh": 396.8, "allTimeLow": 7.65, "priceToSalesTrailing12Months": 13067.316, "fiftyDayAverage": 17.9498, "twoHundredDayAverage": 12.43995, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 260420976, "profitMargins": 0.0, "floatShares": 12170981, "sharesOutstanding": 21218217, "sharesShort": 163125, "sharesShortPriorMonth": 183877, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.0077, "heldPercentInsiders": 0.27677, "heldPercentInstitutions": 0.50159, "shortRatio": 6.13, "shortPercentOfFloat": 0.0092, "impliedSharesOutstanding": 21218217, "bookValue": 17.058, "priceToBook": 1.4802438, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -325660000, "trailingEps": -22.75, "forwardEps": -0.84, "lastSplitFactor": "1:20", "lastSplitDate": 1748822400, "enterpriseToRevenue": 6351.731, "enterpriseToEbitda": -1.412, "52WeekChange": 0.41444445, "SandP52WeekChange": 0.13287461, "quoteType": "EQUITY", "currentPrice": 25.25, "targetHighPrice": 25.0, "targetLowPrice": 12.0, "targetMeanPrice": 19.0, "targetMedianPrice": 20.0, "recommendationMean": 2.66667, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 319624000, "totalCashPerShare": 15.064, "ebitda": -184380992, "totalDebt": 44285000, "quickRatio": 10.026, "currentRatio": 10.296, "totalRevenue": 41000, "debtToEquity": 13.456, "revenuePerShare": 0.003, "returnOnAssets": -0.24162, "returnOnEquity": -0.75751, "grossProfits": 41000, "freeCashflow": -79681128, "operatingCashflow": -165015008, "revenueGrowth": -0.559, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -2483.5332, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1764972120, "regularMarketTime": 1764968400, "marketState": "CLOSED", "regularMarketChangePercent": -0.82482, "regularMarketPrice": 25.25, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623936600000, "postMarketChangePercent": 0.0, "postMarketPrice": 25.25, "postMarketChange": 0.0, "regularMarketChange": -0.209999, "regularMarketDayRange": "24.86 - 25.74", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 45755, "fiftyTwoWeekLowChange": 17.6, "fiftyTwoWeekLowChangePercent": 2.3006537, "fiftyTwoWeekRange": "7.65 - 25.74", "fiftyTwoWeekHighChange": -0.48999977, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -22.75, "epsForward": -0.84, "fiftyDayAverageChange": 7.3001995, "fiftyDayAverageChangePercent": 0.40670088, "twoHundredDayAverageChange": 12.81005, "twoHundredDayAverageChangePercent": 1.029751, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "averageAnalystRating": "2.7 - Hold", "cryptoTradeable": false, "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "fiftyTwoWeekHighChangePercent": -0.019036511, "fiftyTwoWeekChangePercent": 41.444443, "earningsTimestamp": 1762981200, "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2025-12-06"}]